Zandelisib Withdrawn Phase 2 Trials for Chronic Lymphocytic Leukemia Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT05209308Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL